14 October 2016: Nottingham, UK - XenoGesis has invested in a state of the art Agilent AriaMx Real-time PCR system, further expanding its quantitative PCR capabilities and adding CYP induction assays to its portfolio of services.
The Agilent AriaMx Real-time PCR is a fully integrated quantitative PCR amplification, detection and data analysis system and has a 96-well capacity. The machine enables any gene expression assays to be carried out which will expand XenoGesis’ range of assays beyond DMPK to now include pharmacology services.
Senior Research Scientist, Sally Stinson, is leading the introduction of the techniques at XenoGesis and has many years experience carrying out qPCR experiments. Sally adds value through her ability to give in depth advice and carry out experimental work with regards to RNA/cDNA sample preparation from a range of cell types. She can also perform a range of qPCR experiments looking at a variety of genes of interest.
Commenting, Managing Director, Richard Weaver said, “We are continually investing in technology to develop and enhance the capabilities we are able to offer to our clients. This investment means we are now able to offer CYP induction assays and also work with clients to carry out any type of gene expression assays. Furthermore we now have the facility to prepare RNA from a range of cell types and carry out cDNA preparation. Sally’s expertise, and that of the wider team team, will add greater value to clients as we develop these techniques to meet their specific needs.”